TY - JOUR
T1 - Predictors of long-term response to abiraterone in patients with metastastic castration-resistant prostate cancer
T2 - A retrospective cohort study
AU - Verzoni, Elena
AU - De Giorgi, Ugo
AU - Derosa, Lisa
AU - Caffo, Orazio
AU - Boccardo, Francesco
AU - Facchini, Gaetano
AU - Porcu, Luca
AU - De Vincenzo, Fabio
AU - Zaniboni, A.
AU - Chiuri, V. E.
AU - Fratino, Lucia
AU - Santini, Daniele
AU - Adamo, Vincenzo
AU - De Vivo, R.
AU - Dinota, Angelo
AU - Messina, Caterina
AU - Ricotta, Riccardo
AU - Caserta, Claudia
AU - Scavelli, C.
AU - Susi, M.
AU - Tartarone, Alfredo
AU - Surace, G.
AU - Mosca, Alessandra
AU - Bruno, M.
AU - Barni, Sandro
AU - Grassi, Paolo
AU - Procopio, Giuseppe
PY - 2016
Y1 - 2016
N2 - We aimed to identify clinical predictors of long-term response to abiraterone (defined as >12 months drug exposure) in a retrospective cohort of metastatic castration-resistant prostate cancer patients treated in post-docetaxel setting at 24 Italian centers. The Cox proportional hazards model was used to analyze the association between clinical features and the duration of drug exposure. Results were expressed as hazard ratios (HR) with associated 95% confidence intervals (CI). A total of 143 patients met the inclusion criteria. Their median age was 73 years, median Gleason score 8 and median abiraterone exposure 20 months. At the univariate analysis, a significant correlation with the duration of abiraterone exposure was found for Gleason score (HR 0.82, 95% CI 0.71-0.96; p=0.012), PSA (HR 1.10, 95% CI 1.03-1.18; p=0.08) and lactic dehydrogenase levels (HR 1.22, 95% CI 1.02-1.46; p=0.027), while the association between lower alkaline phosphatase levels and treatment duration was marginally significant (HR 1.07, 95% CI 0.99-1.16; p=0.074). Only PSA and Gleason score were predictive of long-term treatment duration in the multivariate analysis. No other clinical factors resulted to be predictive of sustained response to abiraterone, including metastatic disease at diagnosis and visceral disease, suggesting that all subgroups of patients may derive a substantial clinical benefit from abiraterone treatment. These findings need to be validated in prospective, larger studies.
AB - We aimed to identify clinical predictors of long-term response to abiraterone (defined as >12 months drug exposure) in a retrospective cohort of metastatic castration-resistant prostate cancer patients treated in post-docetaxel setting at 24 Italian centers. The Cox proportional hazards model was used to analyze the association between clinical features and the duration of drug exposure. Results were expressed as hazard ratios (HR) with associated 95% confidence intervals (CI). A total of 143 patients met the inclusion criteria. Their median age was 73 years, median Gleason score 8 and median abiraterone exposure 20 months. At the univariate analysis, a significant correlation with the duration of abiraterone exposure was found for Gleason score (HR 0.82, 95% CI 0.71-0.96; p=0.012), PSA (HR 1.10, 95% CI 1.03-1.18; p=0.08) and lactic dehydrogenase levels (HR 1.22, 95% CI 1.02-1.46; p=0.027), while the association between lower alkaline phosphatase levels and treatment duration was marginally significant (HR 1.07, 95% CI 0.99-1.16; p=0.074). Only PSA and Gleason score were predictive of long-term treatment duration in the multivariate analysis. No other clinical factors resulted to be predictive of sustained response to abiraterone, including metastatic disease at diagnosis and visceral disease, suggesting that all subgroups of patients may derive a substantial clinical benefit from abiraterone treatment. These findings need to be validated in prospective, larger studies.
KW - Abiraterone acetate
KW - Castration-resistant
KW - Predictive factors
KW - Prostate cancer
KW - Retrospective studies
UR - http://www.scopus.com/inward/record.url?scp=84982980466&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84982980466&partnerID=8YFLogxK
M3 - Article
VL - 7
SP - 40085
EP - 40094
JO - Oncotarget
JF - Oncotarget
SN - 1949-2553
IS - 26
ER -